Perturbations of 5-Hydroxymethylcytosine Patterning in Hematologic Malignancies

Seminars in Hematology

Volumn 50, Issue 1, 2013, Pages 61-69

  Madzo, Jozef ^a   Vasanthakumar, Aparna ^a   Godley, Lucy A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; 2 OXOGLUTARIC ACID; 5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; CYTOSINE; ISOCITRATE DEHYDROGENASE; PROTEIN TET1; PROTEIN TET2; PROTEIN TET3; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CATALYSIS; CHRONIC MYELOID LEUKEMIA; DNA METHYLATION; DOT HYBRIDIZATION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MUTANT; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; CYTOSINE; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; HEMATOLOGIC NEOPLASMS; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION; PROTO-ONCOGENE PROTEINS;

EID: 84875325570     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.01.004     Document Type: Article

References (76)

1. Florean C., Schnekenburger M., Grandjenette C., Dicato M., Diederich M. Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics 2011, 3:581-609.
2. Martin-Perez D., Piris M.A., Sanchez-Beato M. Polycomb proteins in hematologic malignancies. Blood 2010, 116:5465-5475.
3. Ito S., Shen L., Dai Q., et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333:1300-1303.
4. He Y.F., Li B.Z., Li Z., et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333:1303-1307.
5. Poetsch A.R., Plass C. Transcriptional regulation by DNA methylation. Cancer Treat Rev 2011, 37(Suppl 1):S8-S12.
6. Szulwach K.E., Li X., Li Y., et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci 2011, 14:1607-1616.
7. Bocker M.T., Tuorto F., Raddatz G., et al. Hydroxylation of 5-methylcytosine by TET2 maintains the active state of the mammalian HOXA cluster. Nat Commun 2012, 3:818.
8. Yildirim O., Li R., Hung J.H., et al. Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. Cell 2011, 147:1498-1510.
9. Koh K.P., Yabuuchi A., Rao S., et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 2011, 8:200-213.
10. Iyer L.M., Tahiliani M., Rao A., Aravind L. Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle 2009, 8:1698-1710.
11. Kriaucionis S., Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 2009, 324:929-930.
12. Tahiliani M., Koh K.P., Shen Y., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
13. Dawlaty M.M., Ganz K., Powell B.E., et al. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell 2011, 9:166-175.
14. Moran-Crusio K., Reavie L., Shih A., et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011, 20:11-24.
15. Quivoron C., Couronne L., Della Valle V., et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011, 20:25-38.
16. Li Z., Cai X., Cai C.L., et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011, 118:4509-4518.
17. Ko M., Bandukwala H.S., An J., et al. Ten-eleven-translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A 2011, 108:14566-14571.
18. Shide K., Kameda T., Shimoda H., et al. TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia 2012, 26:2216-2223.
19. Pronier E., Almire C., Mokrani H., et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 2011, 118:2551-2555.
20. Ono R., Taki T., Taketani T., Taniwaki M., Kobayashi H., Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res 2002, 62:4075-4080.
21. Lorsbach R.B., Moore J., Mathew S., Raimondi S.C., Mukatira S.T., Downing J.R. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003, 17:637-641.
22. Burmeister T., Meyer C., Schwartz S., et al. The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group. Blood 2009, 113:4011-4015.
23. Abdel-Wahab O., Mullally A., Hedvat C., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114:144-147.
24. Beer P.A., Delhommeau F., LeCouedic J.P., et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010, 115:2891-2900.
25. Colaizzo D., Tiscia G.L., Pisanelli D., et al. New TET2 gene mutations in patients with myeloproliferative neoplasms and splanchnic vein thrombosis. J Thromb Haemost 2010, 8:1142-1144.
26. Couronne L., Lippert E., Andrieux J., et al. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia 2010, 24:201-203.
27. Flach J., Dicker F., Schnittger S., Kohlmann A., Haferlach T., Haferlach C. Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. Haematologica 2010, 95:518-519.
28. Gelsi-Boyer V., Trouplin V., Adelaide J., et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009, 145:788-800.
29. Jankowska A.M., Szpurka H., Tiu R.V., et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009, 113:6403-6410.
30. Kosmider O., Gelsi-Boyer V., Ciudad M., et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009, 94:1676-1681.
31. Langemeijer S.M., Kuiper R.P., Berends M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41:838-842.
32. Mohamedali A.M., Smith A.E., Gaken J., et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 2009, 27:4002-4006.
33. Nibourel O., Kosmider O., Cheok M., et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 2010, 116:1132-1135.
34. Schaub F.X., Looser R., Li S., et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010, 115:2003-2007.
35. Szpurka H., Jankowska A.M., Makishima H., et al. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leuk Res 2010, 34:969-973.
36. Bacher U., Weissmann S., Kohlmann A., et al. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele. Br J Haematol 2012, 156:67-75.
37. Ko M., Huang Y., Jankowska A.M., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843.
38. Figueroa M.E., Abdel-Wahab O., Lu C., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
39. Yamazaki J., Taby R., Vasanthakumar A., et al. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 2012, 7:201-207.
40. Abdel-Wahab O., Manshouri T., Patel J., et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010, 70:447-452.
41. Dang L., White D.W., Gross S., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010, 465:966.
42. Gross S., Cairns R.A., Minden M.D., et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010, 207:339-344.
43. Ward P.S., Patel J., Wise D.R., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
44. Sjoblom T., Jones S., Wood L.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
45. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
46. Yan H., Parsons D.W., Jin G., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765-773.
47. Marcucci G., Maharry K., Wu Y.Z., et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010, 28:2348-2355.
48. Kosmider O., Gelsi-Boyer V., Cheok M., et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009, 114:3285-3291.
49. Lin J., Yao D.M., Qian J., et al. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol 2012, 91:519-525.
50. Patnaik M.M., Hanson C.A., Hodnefield J.M., et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia 2012, 26:101-105.
51. Chotirat S., Thongnoppakhun W., Promsuwicha O., Boonthimat C., Auewarakul C.U. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. J Hematol Oncol 2012, 5:5.
52. Paschka P., Schlenk R.F., Gaidzik V.I., et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010, 28:3636-3643.
53. Patel J.P., Gonen M., Figueroa M.E., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366:1079-1089.
54. Wyatt G.R., Cohen S.S. A new pyrimidine base from bacteriophage nucleic acids. Nature 1952, 170:1072-1073.
55. Cox G.S., Conway T.W. Template properties of glucose-deficient T-even bacteriophage DNA. J Virol 1973, 12:1279-1287.
56. Jin S.G., Kadam S., Pfeifer G.P. Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine. Nucleic Acids Res 2010, 38:e125.
57. Xu W., Yang H., Liu Y., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
58. Pastor W.A., Pape U.J., Huang Y., et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 2011, 473:394-397.
59. Song C.X., Szulwach K.E., Fu Y., et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol 2011, 29:68-72.
60. Booth M.J., Branco M.R., Ficz G., et al. Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution. Science 2012, 336:934-937.
61. Yu M., Hon G.C., Szulwach K.E., et al. Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. Cell 2012, 149:1368-1380.
62. Abdel-Wahab O., Patel J., Levine R.L. Clinical implications of novel mutations in epigenetic modifiers in AML. Hematol Oncol Clin North Am 2011, 25:1119-1133.
63. Green C.L., Evans C.M., Hills R.K., Burnett A.K., Linch D.C., Gale R.E. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 2010, 116:2779-2782.
64. Green C.L., Evans C.M., Zhao L., et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011, 118:409-412.
65. Delhommeau F., Dupont S., Della Valle V., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289-2301.
66. Hussein K., Abdel-Wahab O., Lasho T.L., et al. Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms. Am J Hematol 2010, 85:81-83.
67. Saint-Martin C., Leroy G., Delhommeau F., et al. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood 2009, 114:1628-1632.
68. Tefferi A., Levine R.L., Lim K.H., et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009, 23:900-904.
69. Tefferi A., Lim K.H., Abdel-Wahab O., et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009, 23:1343-1345.
70. Caramazza D., Lasho T.L., Finke C.M., et al. IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 2010, 24:2120-2122.
71. Patnaik M.M., Lasho T.L., Finke C.M., et al. Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients. Am J Hematol 2011, 86:393-398.
72. Pardanani A., Lasho T., Finke C., Oh S.T., Gotlib J., Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010, 24:1713-1718.
73. Pardanani A., Patnaik M.M., Lasho T.L., et al. Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia 2010, 24:1370-1372.
74. Tefferi A., Lasho T.L., Abdel-Wahab O., et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010, 24:1302-1309.
75. Tang J.Y., Chang C.C., Lin P.C., Chang J.G. Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer. Kaohsiung J Med Sci 2012, 28:138-144.
76. Cairns R.A., Iqbal J., Lemonnier F., et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012, 119:1901-1903.